JO
APVO icon

John Overdeck’s Aptevo Therapeutics APVO Stock Holding History

John Overdeck’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$2.55K – 3192
2024
Q3 		$2.55K Buy
+1
New +$4.6K ﹤0.01% 3075
2021
Q2 		– Hold
0
– -$1.21M – 4021
2021
Q1 		– Hold
0
– – – 2137
2020
Q4 		– Hold
0
– – – 1333
2019
Q2 		– Hold
0
– -$10K – 3300
2019
Q1 		– Hold
0
– – – 2962
2018
Q4 		– Hold
0
– – – 2896

Other funds holding APVO

VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFFP
Center for Financial Planning Southfied, Michigan $1.07B AUM 18.98% 1-Year Est. Return

John Overdeck's APVO Position: Q4 2024 in Review

John Overdeck sold out of Aptevo Therapeutics (APVO) in Q4 2024, closing a stake of 1 share — an estimated $2.55K sold.

John Overdeck first reported a position in APVO in Q3 2024 and held it in 1 quarter. The position peaked at $2.55K in Q3 2024. 7 funds tracked by Wall St. Rank hold APVO as of Q4 2024.

  • John Overdeck reported no remaining Aptevo Therapeutics position as of Q4 2024 after selling out during the quarter.
  • John Overdeck sold 1 Aptevo Therapeutics share in Q4 2024, an estimated $2.55K.
  • John Overdeck first reported a position in Aptevo Therapeutics in Q3 2024 and held it in 1 quarter.
  • John Overdeck's Aptevo Therapeutics position peaked at $2.55K in Q3 2024.
  • 7 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q4 2024.

Based on Two Sigma Investments's 13F filing for Q4 2024, filed 14 Feb 2025.